CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer

CEL-SCI Corporation recently had a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the approval of Multikine for head and neck cancer treatment. The FDA recognizes the urgent need for better therapies in this field and is willing to collaborate with CEL-SCI to demonstrate the effectiveness of Multikine as a potential treatment option. Additionally, CEL-SCI is active..